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Abstract  
Background:  Infliximab and ciclosporin are of similar efficacy in treating acute severe 
ulcerative colitis, but there has been no comparative evaluation of their relative clinical and 
cost effectiveness. 
 
Methods: Between July 2010 and February 2013, 270 patients were recruited at 52 hospitals 
in England, Scotland and Wales to this mixed methods, open-label, parallel-group, pragmatic 
randomised trial. Consenting patients over 18 years old who had been admitted unscheduled 
with severe colitis and failed to respond to intravenous hydrocortisone within about five days, 
were randomised in equal proportions to either infliximab (Remicade
®
 5mg/kg intravenous 
infusion given over two hours at baseline, and again at two and six weeks after the first 
infusion) or ciclosporin (Sandimmun
®
 2 mg/kg/day by continuous infusion for up to seven 
days, followed by twice-daily Neoral
®
 tablets delivering 5·5 mg/kg/day for 11 weeks).  
Randomisation used a web-based password-protected site, with a dynamic algorithm to 
generate allocations on request, thus protecting against investigator preference or other 
subversion, while ensuring that each trial arm was balanced by centre, which was the only 
stratification used.  Local investigators and participants were aware of the treatment allocated, 
but the Chief Investigator and analysts were blinded. Analysis was by treatment allocated. 
Primary outcome was quality-adjusted survival – the area under the curve (AUC) of scores 
from the Crohn’s and Ulcerative Colitis Questionnaire (CUCQ) completed by participants at 
baseline, three and six months, then six monthly over one to three years.  
 
Findings: There was no significant difference in: quality-adjusted survival [analysable data 
from 121 participants (90%) in each group; mean AUC for infliximab 0.705 (sd 0.181) vs 
ciclosporin 0.733 (0.158); mean difference in AUC/day 0·030 favouring ciclosporin; 95% 
confidence interval (CI) from -0·009 to +0·068; p=0·129]; EQ-5D scores; SF-6D scores; 
colectomy rates (55/135 infliximab vs 65/135 ciclosporin, OR=1·350 favouring infliximab, 
95% CI 0·832 to 2·188, p=0.223); time to colectomy (infliximab 810.8 days vs ciclosporin 
744.1; censored data); number of serious adverse reactions (infliximab 16 reactions in 14 
participants vs ciclosporin 10 in nine); serious adverse events (infliximab 21 in 16 vs 
ciclosporin 25 in 17); or deaths (infliximab 3 vs ciclosporin 0, p = 0·247).  
 
Interpretation: There was no significant difference between ciclosporin and infliximab in 
clinical effectiveness. 
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Introduction  
Ulcerative colitis (UC) is a chronic debilitating disease that affects about 150,000 people in 
the UK and 2 million people in Europe.
1,2
 Acute severe ulcerative colitis (ASUC) affects up 
to 25% of patients, either on first presentation or later, and requires hospital admission for 
treatment with intravenous steroids.
3
 About 30% of these patients are resistant to steroid 
therapy and until ten years ago, colectomy was the usual option.
4,5
  
 
Previous studies have proven the efficacy of both ciclosporin and infliximab in the treatment 
of both moderately severe steroid-resistant ulcerative colitis;
6-8
 and acute, severe, steroid-
resistant disease.
9
 However their relative clinical effectiveness and cost effectiveness are not 
known.   
 
Objectives 
To compare the clinical and cost effectiveness of infliximab and ciclosporin in the 
management of patients admitted unscheduled to hospital with ASUC who fail to respond to 
intravenous steroids. 
Methods 
Study design and participants 
We conducted a mixed methods, open-label, parallel-group, pragmatic randomised trial in 52 
district general and teaching hospitals across England, Scotland and Wales.
10
 . Potential 
participants were identified following unscheduled admission with severe UC.  Patients over 
18 were recruited to the trial if they failed to respond
 
to between two and about five days of 
intravenous hydrocortisone, with continuing severe disease according to Truelove & Witts’ 
criteria
11
 or clinical judgement. All patients had either a proven histological diagnosis of 
ulcerative colitis, or indeterminate colitis where clinical judgement suggested a diagnosis of 
ulcerative colitis rather than Crohn’s disease, or symptoms typical of ulcerative colitis 
subsequently confirmed on histology of a colonic biopsy taken soon after admission. 
 
We excluded patients under 18 years; from vulnerable groups or unable to consent; with an 
enteric infection or histological diagnosis inconsistent with UC; pregnant, lactating, or fertile 
but unwilling to use contraception for six months after randomisation; with serious co-
morbidity, including current malignancy (except for basal cell carcinoma), 
immunodeficiency, recent myocardial infarction, heart failure, acute stroke, respiratory 
failure, renal failure, hepatic failure or severe infection; known to be hypersensitive to 
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infliximab, ciclosporin or polyethoxylated oils; taking tacrolimus or rosuvastatin; needing 
emergency colectomy without further medical treatment; treated with either infliximab or 
ciclosporin in the three months before admission; with any other contraindication to treatment 
with infliximab or ciclosporin; participating in another clinical trial; or with poor English 
without available translation. 
 
Because we anticipated difficulty in obtaining informed consent and baseline data from 
acutely and severely ill patients whose health was worsening, we explained the trial to 
patients with known or suspected ASUC as soon as possible after admission and, with 
consent, asked them to complete a baseline quality of life questionnaire.  This created a 
‘cohort’ of patients with ASUC from which we recruited to the trial those who failed to 
respond to treatment with intravenous hydrocortisone, following further explanation and 
consent.  The treatment of patients who did not consent to either cohort or trial was 
unaffected.  The protocol, patient information sheets and consent forms, all questionnaires 
and amendments were approved by the Research Ethics Committee for Wales 
(08/MRE09/42) and local Research and Development Committees. 
Randomisation and masking 
Eligible patients were invited to participate by local investigators.  Following full explanation 
and written consent, their details were entered onto a web-based password-protected site 
(hosted by Bangor University), and allocated at random to infliximab or ciclosporin. A 
dynamic algorithm
12
 was used to generate allocations on request, thus protecting against 
investigator preference or other subversion while ensuring that each trial arm was balanced by 
centre, which was the only stratification used.   
 
As this was an open-label trial, local investigators and participants were aware of the 
treatment allocated, but the Chief Investigator and all analysts remained blinded to allocation 
until the Trial Steering Committee and Data Monitoring and Ethics Committee had reviewed 
and approved the analysis of the primary outcome. 
 
Procedures 
Patients randomised to infliximab received Remicade
®
 5mg/kg by intravenous infusion, given 
over two hours at baseline, and again at two and six weeks after the first infusion, in 
accordance with local prescribing guidelines.  
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Patients randomised to ciclosporin received Sandimmun
®
 by continuous infusion of 2 
mg/kg/day, continued for up to seven days if successful; then twice-daily Neoral
®
 tablets 
delivering 5·5 mg/kg/day, with the dose adjusted to achieve trough ciclosporin concentration 
of 100 – 200 ng/ml for 12 weeks. The drugs were dispensed by hospital pharmacies, as part of 
routine practice. They were not provided specifically for the trial by pharmaceutical 
companies, who did not support this trial in any way. 
 
We did not mandate other therapy. Centres were encouraged to give co-trimoxazole as 
prophylaxis against Pneumocystis jiroveci (carinii) pneumonia, and given discretion to start 
azathioprine or 6-mercaptopurine at therapeutic doses in week 4. Guidance included stopping 
steroids by week 12 in patients who remained well, but to restart steroids in patients who 
became symptomatic. After 12 weeks, all treatment was at the discretion of the patient’s 
physician. 
 
Outcomes 
Because we wished to compare the effectiveness of treatment as perceived by patients over at 
least a year, during which time they may experience many different health states including a 
post-colectomy stoma, we used quality–adjusted survival (QAS)13 as the primary outcome 
measure.  This was measured as the total area under the curve (Figure 1) described by scores 
from the Crohn’s and Ulcerative Colitis Questionnaire (CUCQ),14,15 which was completed by 
participants at baseline, three and six months, then six monthly over one to three years. If a 
participant underwent colectomy, additional questions were completed on post-operative 
discharge and four, eight and 12 weeks, and then six monthly. The CUCQ and its colectomy 
extension were developed by modifying and concurrently validating the UK Inflammatory 
Bowel Disease Questionnaire (UK-IBDQ)
16
 to be appropriate for use by patients across a 
spectrum of disease states, including quiescent, mild chronic, and and acute severe colitis, and 
post-colectomy. Although by convention low scores indicate better health on disease-specific 
patient-reported outcome measures (PROMs), for the purposes of presenting the area under 
the curve, the CUCQ score was transformed so that a lower score indicated worse health.  
 
Secondary outcome measures included: change in CUCQ scores, and those from two generic 
quality of life measures (SF-12, from which the SF-6D was derived, and EQ-5D), completed 
by participants at the time intervals described above.  Case report forms were completed by 
local research professionals, and from these were derived mortality; incidence of colectomy, 
both emergency and planned; length of stay; and incidence of malignancies, serious infections 
and renal disorders. Adverse events were monitored via reports from Principal Investigators, 
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and used to triangulate the incidence of malignancies, serious infections and renal disorders. 
All incident malignancies were classified as ‘possibly related’ to the treatment received.  
Because of differing pharmacokinetics, we classified infections as ‘possibly related’ if the 
diagnosis was within one month of the last dose of ciclosporin, or six months after infliximab. 
Thereafter they were classified as ‘unlikely to be related’. New symptoms arising after 
treatment were documented in adverse event reports, and analysed and analysed by clinical 
system affected when associated with readmission. 
 
Statistical analysis 
Our hypothesis was that there is no difference in the clinical effectiveness of these two 
treatments, as measured by quality of life.  Our original target sample size was 360 
participants with analysable data, based on an equivalence design, an effect size of 0·30, and a 
primary outcome of change in CUCQ scores at two years. In 2012, slower recruitment than 
predicted led us to reduce the analysable sample size to 250, still sufficient to detect an effect 
size of 0·35 with 80% power at 5% significance level.   To mitigate the effect of attrition we 
introduced a length of follow-up of one to three years, and redefined our primary outcome as 
QAS, measured as the area under the curve described by CUCQ scores (including after 
colectomy).  
 
Primary analysis was by treatment allocated, reflecting the pragmatic nature of the trial 
design. The primary outcome measure used a general linear model to estimate differences in 
QAS between groups, adjusting for covariates including: trial site; age; gender; ethnic group; 
social deprivation (derived from truncated post-codes); baseline quality of life; disease 
severity; and time in follow-up. 
 
Secondary analyses adjusted for the same covariates as primary analysis and compared 
between groups: QAS per day (again using general linear models); CUCQ scores (using 
methods for repeated measures); proportion of participants undergoing colectomy (using 
binary logistic regression); time to colectomy (censored at the end of follow up, and analysed 
by Cox regression); proportion of participants suffering one or more adverse events (using 
binary logistic regression); and mortality. 
 
Residual diagnostics were examined in analyses that assume Normality, with the options of 
data transformation and boot-strapping when residual distributions were markedly non-
Normal. Identified outliers were excluded and the revised datasets reanalysed. Analyses are 
summarised by descriptive comparisons between groups in accordance with CONSORT 
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guidelines
17
, notably estimates with 95% confidence intervals representing two-tailed tests at 
the 5% significance level. 
 
This was a mixed methods trial which also evaluated cost effectiveness, through a cost utility 
study conducted alongside the clinical trial.  The methods and results are available in detail 
elsewhere.
15
 In summary, costs were assessed by prospectively monitoring total health service 
resource use by patients in both arms of the trial, collected in case report forms at each follow 
up. These data were multiplied by relevant unit costs and expressed in 2012-13 prices. 
Effectiveness was assessed in terms of Quality Adjusted Life Year (QALY) generated from 
EQ-5D data. 
We also sought the views of patients and professionals during this mixed methods study.  The 
method and findings are report in full elsewhere
15 
and summarised in the on-line appendix to 
this paper. 
 
The study is registered as an International Standard Randomised Controlled Trial, number 
ISRCTN 22663589. 
 
 Role of the funding source 
The trial was funded by the NIHR Health Technology Assessment Programme (project 
number 06/78/03).  The funder had no role in the design of the study apart from the detailed 
scrutiny and feedback from their independent peer reviewers before funding was awarded. 
The views and opinions expressed are those of the authors and do not necessarily reflect those 
of the Department of Health.  The trial was sponsored by Swansea University, whose clinical 
trials unit contributed to the design of the study, analysis and reporting of the data through 
AW and HH.  AW, HH, DC, FA, ML, JMM and JGW had access to the raw data, but 
remained blind to allocations until the analysis of the primary outcome had been approved at 
a joint meeting of the Trial Steering Committee and Data Monitoring Committee.       
 
Results 
Patient flow 
Between May 2010 and February 2013, 2065 potentially eligible patients were admitted to 62 
hospitals in England, Scotland and Wales, and 1614 of those were consented into the cohort.  
From July 2010 until March 2013, 270 of these patients were recruited into the trial at 52 
hospitals, and were followed for one to three years until follow-up ceased in February 2014. 
There were 135 patients in each arm (Figure 2a), of whom 242 (90%) contributed to definitive 
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analysis of the primary outcome (Figures 2b). Median follow-up (IQR) was 765 days (398 
days) overall [766 days (404 days) for infliximab, and 764 days (385 days) for ciclosporin].  
At baseline, there were no statistically significant differences between the groups in 
demographic, disease characteristics, haemoglobin, inflammatory markers, albumin, or 
quality of life scores (Table 1). The mean duration of treatment with intravenous steroids was 
similar in both groups (5.32 days, sd 2.66 before infliximab; 5.43 days, sd 2.89 before 
ciclosporin).  Failure to respond was assessed by clinical judgement rather than Truelove and 
Witts scores in 36 patients in both groups.  
 
Primary outcome 
There was no significant difference in QAS between infliximab and ciclosporin: the observed 
means (standard deviations) for total area under the CUCQ curve were 564.0 (241.9) and 
587.0 (226.2), respectively, and the mean adjusted difference was 7.9 favouring ciclosporin 
[95% confidence interval (CI) from -22·0 to 37·8; p = 0·603]. The observed means (standard 
deviations) in AUC/day were 0.705 (0.181) and 0.733 (0.158) for infliximab and ciclosporin, 
respectively, and mean adjusted difference in AUC/day was 0.030, favouring ciclosporin 
(95% CI from -0·009 to 0·068; p = 0·129] (Table 2). 
Secondary outcomes 
At no time after randomisation was there any significant difference between allocated groups 
for: CUCQ scores (mean adjusted difference in AUC/day of survivors = 0·020 favouring 
ciclosporin; 95% CI from -0·019 to 0·0581; p=0·319) (Figure 3), SF-6D scores (mean 
adjusted difference = 0·005 favouring ciclosporin; 95% CI from -0·025 to 0·035; p=0·737) 
(Figure 4); or EQ-5D scores (QALY mean adjusted difference = 0·021 favouring ciclosporin; 
95% CI from -0·032 to 0·096; p=0·350) (Figure 5). There was also no significant difference 
between allocated groups in colectomy rates [in-hospital: 29/135 (21.5%) on infliximab 
versus 34/135 on ciclosporin (25.2%); at 3 months: 39/135 (28.9%) versus 41/135 (30.4%); 
12 months: 47/135 (34.8%) versus 61/135 (45.2%); overall: 55/135 (40.7%) versus 65/135 
(48.1%); odds ratio (OR) =1·350 favouring infliximab; 95% CI from 0·832 to 2·188; p = 
0·223]; or time to colectomy (mean 811 days on infliximab versus 744 days; hazard ratio = 
1·234 favouring infliximab; 95% CI from 0·862 to 1·768; p = 0.251) [Figure 6]. Although 
length of stay after randomisation ostensibly did not differ between allocated groups (mean 
adjusted difference = 1·542 days more for ciclosporin; 95% CI from -1·297 to 4·381 
assuming Normal distribution of residuals in general linear model; p = 0·286), the distribution 
was so skewed as to invalidate the assumption of Normality. Stays were therefore 
transformed by taking logarithms and stay after first dose of ciclosporin was a factor of 1·523 
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times longer than that after first dose of infliximab (95% CI from factor of 1·278 to factor of 
1·817; p < 0·0001) (Table 2). Treatment with infliximab was continued for longer than 
ciclosporin after the designated intervention period (Figure 7); no-one received ciclosporin 
after six months, but many participants continued to receive  infliximab for two years or 
more, resulting in mean treatment durations of 126 days for infliximab versus 56 days for 
ciclosporin. Median treatment duration was 43 days for infliximab versus 60 days for 
ciclosporin. Nine participants randomised to ciclosporin were subsequently given infliximab 
(four at three months; two at six; and three at 12 months after randomisation).  One 
participant randomised to infliximab received oral ciclosporin at three months. There were no 
significant differences between the two arms of the study in use of azathioprine, 6-
mercaptopurine, or methotrexate at any time point (Table 3), either when given alone or in 
combination.  
Adverse Events 
There was no statistically significant difference between the two drugs in serious adverse 
reactions (SARs), or serious adverse events (SAEs): 16 reactions in 14 participants given 
infliximab and 10 in nine given ciclosporin were classified as SARs (event ratio = 0·938 
favouring ciclosporin; 95% CI from 0·590 to 1·493; p = 0·788) [Table 4]. 21 events in 16 
participants given infliximab and 25 in 17 given ciclosporin were classified as SAEs not 
related to disease progression or colectomy (event ratio = 1.075 favouring infliximab; 95% CI 
0·603 to 1.917; p = 0·807).   Table 4 shows the clinical systems affected for SARs. There 
were two malignancies on infliximab (basal cell carcinoma and colorectal cancer), and one on 
ciclosporin (endometrial cancer). Eleven participants were noted to have impaired renal 
function on ciclosporin but only one was reported as a serious adverse reaction, and all 
resolved with dose reduction.  More infections were attributed to infliximab (8/135; 5.9%) 
than ciclosporin  (1/135; 0.7%), but more SAEs due to an infection unrelated to the 
intervention occurred after ciclosporin (16/135;11.9%) than infliximab (8/135; 5.9%).   Three 
patients died, all after taking infliximab (p = 0·247): two of perioperative pneumonia with 
sepsis (at 20 and 65 days following start of treatment; both had multiple co-morbidities 
including diabetes); and one of disseminated colorectal cancer (at 278 days, 20 years after UC 
was first diagnosed).  
 
The cost-utility analysis found that total health service cost over 30 months were £5632 
higher for infliximab patients, due mainly to the higher acquisition costs for infliximab (95% 
CI £2,773 to £8,305, p<0.001).  Effectiveness over this period was similar in both groups, and 
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a mean adjusted difference of 0.21 QALYs in favour of ciclosporin was not statistically 
significant (95% CI from -0.032 to 0.096; p=0.350.    
 
Discussion 
CONSTRUCT has shown that both infliximab and ciclosporin improve quality of life in 
patients suffering from acute severe colitis that has not responded to intravenous steroids. 
Nevertheless, 40% of patients (108/270) still undergo colectomy within one year. There was 
no significant difference between allocated treatment in terms of quality of life, colectomy 
rates, adverse events, or mortality, even though three patients died of complications that were 
possibly related to infliximab (two sepsis and one cancer).   Although more infections were 
thought to be possibly related to infliximab (8) than ciclosporin (1) participants were treated 
with infliximab for longer, and differing pharmacokinetics were also taken into account when 
assessing the length of time over which relatedness was possible. 
 
The trial was pragmatic, conducted in 52 hospitals, and designed to reflect current clinical 
practice across the UK. Local investigators were aware of treatment allocations, but the Chief 
Investigator and analysts remained blind to allocations until the Trial Steering and Data 
Monitoring Committees had approved the analysis of the primary outcome.  The protocol 
mandated either three infusions of infliximab over six weeks, or intravenous ciclosporin for 
up to seven days, followed by oral administration for 12 weeks.  After this, principal 
investigators were given discretion to continue or stop treatment. In keeping with current 
practice, infliximab tended to be used for longer than ciclosporin (with similar medians, but a 
mean difference of 70 days). Although this may have improved the effectiveness of 
infliximab, it certainly increased costs. Treatment with immunosuppressants during and after 
infliximab or ciclosporin was similar in both groups. Neither the rate nor timing of colectomy 
differed between allocated groups. Importantly post-colectomy quality of life scores and 
interviews with participants who had undergone surgery both suggest that colectomy is not a 
bad outcome. There is evidence from observational studies that the cumulative rate of 
colectomy rises over time, not only with ciclosporin, but also with infliximab.
18-24
 Hence we 
plan to follow the trial and cohort participants for ten years following recruitment, using 
routine NHS data to monitor readmissions and colectomies, with annual questionnaires to 
monitor trial patients’ quality of life. 
 
To measure effectiveness from a patient perspective we used the CUCQ, a 32 item 
questionnaire with an additional ten questions for patients with a stoma.  This PROM was 
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derived from the UKIBDQ
16
, and validated concurrently during the trial.
15
 We used it to 
assess quality of life of participants over one to three years as they passed through different 
health states, including colectomy and stoma.  The concept of quality adjusted survival (QAS) 
is not new
13
, but it is the first time it has been applied to inflammatory bowel disease. 
 
Our findings of equivalent effectiveness reinforce the efficacy findings of CySIF
9
, a European 
trial which assessed treatment failure at three months as the primary outcome. Three year 
follow-up data from CySIF reported in oral presentation in 2015 do not show differences in 
colectomy rate, even though a majority of patients continued infliximab and many allocated to 
ciclosporin subsequently switched to infliximab
25
 
 
The cost utility analysis found that UK NHS costs over 30 months were £5632 higher for 
infliximab patients, due mainly to the higher acquisition costs for infliximab.   On this basis, 
ciclosporin is the more cost effective treatment in the UK, although differences in the cost of 
ciclosporin and infliximab are apparent world-wide. With the advent of anti-TNF biosimilars, 
the cost of infliximab is falling.
26
 Nevertheless, while the cost remains higher than ciclosporin 
our findings question the justification of treating patients with infliximab as it does not 
produce any additional health benefits.  While we accept that economic grounds are not the 
only grounds for decision making, the opportunity cost to other patients has to be borne in 
mind when choosing a treatment option that is not cost effective.     
 
We note that the US Food and Drug Administration has expressed its dissatisfaction with 
current use of disease activity scores as primary endpoints in IBD trials, and is moving 
towards Patient Reported Outcome measures.
27
 CONSTRUCT is the first major pragmatic 
drug trial in inflammatory bowel disease to employ a disease specific PROM to assess 
primary outcome, and used an instrument that enabled measurement of change in quality of 
life through different disease states, including after surgery.  This will provide a benchmark 
for the evaluation of re-costed infliximab, and a model for evaluating newer biologic 
treatments or colonic release preparations of ciclosporin.
28
 We hope our innovative approach 
will be also be a model for IBD trials in the future. 
 
Conclusions   
There are no significant differences in clinical effectiveness, colectomy rates, incidence of 
serious adverse reactions or mortality following treatment with ciclosporin or infliximab for 
patients with ASUC who do not respond to treatment with intravenous steroids.  
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